AIM: Several studies consider 124I PET useful in the evaluation of differentiated thyroid cancer (DTC). The aim of this work was to evaluate the usefulness of 124I positron emission tomography (PET)/computed tomography (CT) for: 1) pretherapeutic staging; 2) optimizing the administering activity in case of remnants ablation; 3) individualizing a complex dosimetry case by case especially in plurimetastatic patients. METHODS: A total of 69 patients were studied in our department between September 2007 and June 2008: 17 male and 52 female, aged 17-83 (mean age 46.6) and, with a simplified method, an expectation dose with a distant therapeutic evaluation, in term of efficacy, was calculated. A total body 124I PET/CT and a whole body scan (WBS) were done, respectively, before and after radiometabolic therapy with 131I and then compared in double blind in 67/69. In 2/69 with a follicular plurimetastatic DTC (both female, aged 65 and 71), an individualized complex dosimetric study was done. RESULTS: PET/CT and WBS matched in 58/67 patients (86.6%). We obtained a complete ablation of the thyroid remnants in 60/67 patients (90%). The individualized complex dosimetry tells us that the administrable maximum activity is for: patient 1:13320 MBq and patient 2:9250 MBq. CONCLUSIONS: Iodine-124 PET/CT is a powerful diagnostic tool before administration of 131I therapeutic dose. It allows for a precise dosimetry in plurimetastatic patients. After an empiric dose estimation, the successful percentage in term of thyroid's remnants ablation was very elevated.
AIM: Several studies consider 124I PET useful in the evaluation of differentiated thyroid cancer (DTC). The aim of this work was to evaluate the usefulness of 124I positron emission tomography (PET)/computed tomography (CT) for: 1) pretherapeutic staging; 2) optimizing the administering activity in case of remnants ablation; 3) individualizing a complex dosimetry case by case especially in plurimetastatic patients. METHODS: A total of 69 patients were studied in our department between September 2007 and June 2008: 17 male and 52 female, aged 17-83 (mean age 46.6) and, with a simplified method, an expectation dose with a distant therapeutic evaluation, in term of efficacy, was calculated. A total body 124I PET/CT and a whole body scan (WBS) were done, respectively, before and after radiometabolic therapy with 131I and then compared in double blind in 67/69. In 2/69 with a follicular plurimetastatic DTC (both female, aged 65 and 71), an individualized complex dosimetric study was done. RESULTS: PET/CT and WBS matched in 58/67 patients (86.6%). We obtained a complete ablation of the thyroid remnants in 60/67 patients (90%). The individualized complex dosimetry tells us that the administrable maximum activity is for: patient 1:13320 MBq and patient 2:9250 MBq. CONCLUSIONS:Iodine-124 PET/CT is a powerful diagnostic tool before administration of 131I therapeutic dose. It allows for a precise dosimetry in plurimetastatic patients. After an empiric dose estimation, the successful percentage in term of thyroid's remnants ablation was very elevated.
Authors: Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-12 Impact factor: 9.236
Authors: Chang-Lae Lee; Hilla Wahnishe; George A Sayre; Hyo-Min Cho; Hee-Joung Kim; Miguel Hernandez-Pampaloni; Randall A Hawkins; Shorouk F Dannoon; Henry F VanBrocklin; Melissa Itsara; William A Weiss; Xiaodong Yang; Daphne A Haas-Kogan; Katherine K Matthay; Youngho Seo Journal: Med Phys Date: 2010-09 Impact factor: 4.071
Authors: Filippo Galli; Isabella Manni; Giulia Piaggio; Lajos Balogh; Bruce D Weintraub; Mariusz W Szkudlinski; Valerie Fremont; Rudi A J O Dierckx; Alberto Signore Journal: Thyroid Date: 2014-06-20 Impact factor: 6.568
Authors: Gauri R Khorjekar; Douglas Van Nostrand; Carlos Garcia; Jeffrey O'Neil; Shari Moreau; Francis B Atkins; Mihriye Mete; Michael H Orquiza; Kenneth Burman; Leonard Wartofsky Journal: Thyroid Date: 2014-06-20 Impact factor: 6.568
Authors: Massimiliano Pacilio; Miriam Conte; Viviana Frantellizzi; Maria Silvia De Feo; Antonio Rosario Pisani; Andrea Marongiu; Susanna Nuvoli; Giuseppe Rubini; Angela Spanu; Giuseppe De Vincentis Journal: Diagnostics (Basel) Date: 2022-07-21